The most impactful development was the rapid success of Moderna's COVID-19 vaccine, Spikevax, which witnessed massive demand during the pandemic. Starting in early 2021, regulatory approvals from ...

In December 2020, both Moderna's Spikevax and Pfizer / BioNTech's Comirnaty COVID vaccines received emergency use authorization (“EUA”) in the US. Both used a pioneering new mechanism of ...

A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ ... best known as the producer of the Spikevax COVID vaccine, pushed its stock nearly 16% higher during ...

Earlier that day, a court in Düsseldorf, Germany ruled that a COVID patent held by Moderna had been violated by a pair of rivals, American pharmaceutical giant Pfizer and its partner, German ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

Pfizer and BioNTech earned more than $3.3 billion in revenue from global sales of their vaccine Comirnaty last year, while Moderna earned $3.2 billion from its vaccine Spikevax, according to ...

Moderna collected $3.1 billion in 2024 Spikevax sales and $25 million from its newer mRESVIA. At its peak in 2022, Spikevax brought in $18.4 billion for the company.

Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax and, where applicable, additional Moderna products that Moderna has represented use the same LNP technology ...

Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax® and, where applicable, additional Moderna products that Moderna has represented use the same LNP technology ...

Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax ® and, where applicable, additional Moderna products that Moderna has represented use the same LNP technology, ...